New Delhi: Drug firm Glenmark on Wednesday said it has received approval from the US health regulator to market a generic drug to treat conditions caused by too much acid production in the stomach.
Glenmark Specialty SA has received final approval from the US Food and Drug Administration (USFDA) for esomeprazole magnesium delayed-release capsules, the drugmaker said in a statement.
The company's product is the generic version of Halon US Holdings LLC's Nexium.
According to Nielsen syndicated data for the latest 52-week period ending May 18, 2024, Nexium 24 HR delayed-release capsules (20 mg) achieved annual sales of approximately US$259.2 million.
Glenmark shares were trading 0.55 per cent lower at Rs 1,185 on BSE.
Glenmark Specialty SA has received final approval from the US Food and Drug Administration (USFDA) for esomeprazole magnesium delayed-release capsules, the drugmaker said in a statement.
The company's product is the generic version of Halon US Holdings LLC's Nexium.
According to Nielsen syndicated data for the latest 52-week period ending May 18, 2024, Nexium 24 HR delayed-release capsules (20 mg) achieved annual sales of approximately US$259.2 million.
Glenmark shares were trading 0.55 per cent lower at Rs 1,185 on BSE.
